STK899704

STK899704 is a tubulin polymerization inhibitor. STK899704 exhibits broad-spectrum inhibitory activity against various cancer cell lines with IC50 values ranging from 0.2 to 1.0 μM. STK899704 disrupts the mitotic spindle structure, inducing G2/M phase cell cycle arrest. STK899704 inhibits the migration ability of HT29 cells by downregulating the FAK-MEK-ERK signaling pathway, thereby suppressing the expression and activity of MMP-2 and MMP-9. STK899704 activates caspase-3/7/8/9, leading to PARP cleavage and inducing apoptosis. STK899704 induces cellular senescence through the p53 pathway. STK899704 can be used in research on skin cancer, lung cancer, colon cancer, and other cancers[1][2][3].

Product Specifications

CAS Number

[1578247-29-6]

UNSPSC

12352005

Target

Apoptosis; Caspase; ERK; FAK; MDM-2/p53; MEK; Microtubule/Tubulin; MMP; PARP

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=C(OCC)CN1C(C)=C(/C=N/NC(C2=CC3=C4C=CC=CC4=CC=C3O2)=O)C5=C1C=CC=C5

Molecular Formula

C27H23N3O4

Molecular Weight

453.49

References & Citations

[1]Park CW, et al. The Novel Small Molecule STK899704 Promotes Senescence of the Human A549 NSCLC Cells by Inducing DNA Damage Responses and Cell Cycle Arrest. Front Pharmacol. 2018 Apr 16;9:163.|[2]Jang HJ, et al. STK899704 inhibits stemness of cancer stem cells and migration via the FAK-MEK-ERK pathway in HT29 cells. BMB Rep. 2018 Nov;51 (11) :596-601.|[3]Sakchaisri K, et al. Anticancer activity of a novel small molecule tubulin inhibitor STK899704. PLoS One. 2017 Mar 15;12 (3) :e0173311.